ATYR Overview

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

aTyr Pharma Inc revenue for the last quarter amounts to 0.00 USD, decreased

aTyr Pharma Inc. EPS for the last quarter amounts to -0.14 USD, decreased -22.22

aTyr Pharma Inc (ATYR) has 56 emplpoyees as of March 16 2026.

Today ATYR has the market capitalization of 83.34M USD.